Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06354660

Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

Diabetes Type 2 Clinical Trial

Official title:
A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

Clinical Trial Summary

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06354660
Study type Interventional
Source Eli Lilly and Company
Contact There may be multiple sites in this clinical trial. 1-877-CTLILL
Phone 1-317-615-4559
Email ClinicalTrials.gov@lilly.com
Status Recruiting
Phase Phase 3
Start date April 10, 2024
Completion date July 2026
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Active, not recruiting NCT04954313 - Baseline Oral Health Study: UnCoVer the Connections to General Health Phase 4
Not yet recruiting NCT06437782 - Exploration of Health Literacy in Diabetes in Reunion Island and France
Completed NCT01354925 - Management of Type-2 Diabetic Patients Treated With Insulin During the Ramadan Phase 4
Completed NCT01206725 - Exercise Study on Cardiac Function in Patients With Diabetes Mellitus Type 2 and Diastolic Dysfunction N/A
Completed NCT00997282 - A Study of OPC-262 in Patients With Type 2 Diabetes Phase 2/Phase 3
Completed NCT00637546 - Gait and Balance of Diabetes Type 2 Patients Phase 2/Phase 3
Completed NCT00464880 - Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy Phase 1/Phase 2
Withdrawn NCT02057497 - An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms N/A
Active, not recruiting NCT05014204 - Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes N/A
Recruiting NCT03662217 - Personalized Nutrition for Diabetes Type 2 N/A
Completed NCT04276051 - Cryovagotomy Diabetes Trial N/A
Completed NCT02569684 - Effects of Prebiotics on GLP-1 in Type 2 Diabetes N/A
Active, not recruiting NCT01933529 - ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes) Phase 2
Terminated NCT01722474 - Assessment of Three Instruments for the Non-invasive Measurement of Arterial Stiffness. N/A
Completed NCT00977262 - Postprandial Inflammation and Fatty Acids N/A
Completed NCT00518427 - Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine Phase 4
Recruiting NCT05378620 - Project Dulce for Filipino-Americans With Type 2 Diabetes N/A
Recruiting NCT03834207 - A Study of the Usefulness & Usability of a Healthcare IT System for Managing Multi-morbidity and Poly-pharmacy N/A
Active, not recruiting NCT05228067 - Enhancing Brain Health by tDCS in Persons With Overweight and Obesity N/A